BIOTECH MARKET RESEARCH $AVTX | Ep. 954
Relay Therapeutics
Avalo Therapeutics ($AVTX) has become a catalyst-driven trade into its Phase II LOTUS readout for AVTX-009 in hidradenitis suppurativa (HS) expected April–May 2026, with investors framing the dataset as a referendum on whether selective IL-1β inhibition can reproduce or exceed the efficacy signal previously observed with broader IL-1 blockade in HS. The stock likely only re-rates if the readout demonstrates HiSCR75 response rates in the ~40–50% range at week 16, establishing clear activity versus placebo and reinforcing the thesis that IL-1β sits upstream of TNF and IL-17 inflammatory signaling in HS. Investors will overweight absolute HiSCR75 response, dose separation between the Q2W and Q4W regimens, performance in biologic-experienced patients, and whether responses approach or exceed the efficacy benchmarks seen with IL-17 programs and AbbVie’s lutikizumab Phase II dataset. Safety will also matter, particularly whether AVTX-009 maintains a clean infection and discontinuation profile consistent with prior IL-1 biologics while supporting the longer dosing interval enabled by its ~19-day half-life. If the LOTUS dataset shows HiSCR75 responses compressing into the ~25–30% range, weak dose differentiation, or high placebo-adjusted noise typical of HS trials, the narrative shifts toward mechanistic overreach and Phase II uncertainty, pressuring confidence in IL-1β as a clinically meaningful driver of HS and pushing AVTX back toward a binary, capital-intensive Phase III story rather than a de-risked best-in-class immunology setup. Options are pricing +/- 185% volatility.
Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.
We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).
Be sure to SUBSCRIBE to not miss.
HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS
While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.
This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.
🚨 ALERT: Phase Il data for AVTX-009 in hidradenitis suppurative (April/May)
📅 TIMING: April/May 2026
📈 IMPLIED MOVE: ~±185%
BACKGROUND:
